SCHEMBL472242

SCHEMBL472242

CC(=O)c1cc2cccc(O)c2nc1C(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.50
MAOA P21397 1/20 0.50
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 5/20 0.44
METAP2 P50579 1/20 0.43
PIM1 P11309 1/20 0.42
THRB P10828 1/20 0.41
GRIN2D O15399 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
PLAU P00749 1/20 0.40
NCF1 P14598 1/20 0.40
ALDH1A1 P00352 2/20 0.39
ALOX12 P18054 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 2/20 0.39
PDE4D Q08499 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18106135 0.83 KMT2A (0.55) MAOBMAOAKMT2AMEN1KDM4E
SCHEMBL30084798 0.75 CCR1 (0.47) KMT2AMEN1KDM4EALDH1A1LMNA
SCHEMBL27828993 0.74 IKBKB (0.50) MAOBMAOAKMT2AMEN1KDM4E
SCHEMBL6277586 0.73 KMT2A (0.55) MAOAKMT2AMEN1KDM4EMETAP2
SCHEMBL6565245 0.72 DAO (0.41) MAOBMAOAKMT2AMEN1KDM4E
SCHEMBL3246323 0.71 METAP2 (0.56) KMT2AMEN1KDM4EMETAP2PIM1
SCHEMBL11871238 0.71 KMT2A (0.45) KMT2AMEN1KDM4EMETAP2PIM1
SCHEMBL1051386 0.70 KDM4E (0.71) KMT2AMEN1KDM4EMETAP2PIM1
SCHEMBL28255583 0.70 KDM4E (0.51) MAOAKMT2AMEN1KDM4EMETAP2
SCHEMBL28756690 0.70 KDM4E (0.51) KMT2AMEN1KDM4EMETAP2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0327934-A1 Device and method for carrying out extemporaneous quantitative diagnostic tests on the whole blood Beli, Raffaele (IT) 1989-08-16 EP claimed
US-11898180-B2 Compositions and methods for amino acid depletion therapy AVALON POLYTOM (HK) LIMITED (HK) 2024-02-13 US disclosed
US-20240009283-A1 Compositions Of Engineered Human Arginases And Methods For Treating Cancer AERASE, INC. (US) 2024-01-11 US disclosed
EP-3778885-B1 COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER AERASE INC (US) 2023-03-08 EP disclosed
EP-3957727-A1 COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER AERase, Inc. (US) 2022-02-23 EP disclosed
EP-3957728-A1 COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER AERase, Inc. (US) 2022-02-23 EP disclosed
US-20210189370-A1 COMPOSITIONS AND METHODS FOR AMINO ACID DEPLETION THERAPY AVALON POLYTOM (HK) LIMITED (HK) 2021-06-24 US disclosed
US-20210128703-A1 Compositions Of Engineered Human Arginases And Methods For Treating Cancer AERASE, INC. (US) 2021-05-06 US disclosed
EP-3778885-A1 COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER AERase, Inc. (US) 2021-02-17 EP disclosed
EP-3064579-B1 PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES OF ENGINEERED HUMAN ARGINASES AERASE INC (US) 2020-09-30 EP disclosed
US-8440184-B2 Compositions of engineered human arginases and methods for treating cancer GMA TECHNOLOGIES LLC (US) 2013-05-14 US disclosed
US-20120177628-A1 ARGINASE FORMULATIONS AND METHODS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-07-12 US disclosed
EP-2449102-A2 ARGINASE FORMULATIONS AND METHODS The Board of Regents of The University of Texas System (US) 2012-05-09 EP disclosed
EP-2411040-A1 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents The Hong Kong Polytechnic University (CN) 2012-02-01 EP disclosed
EP-2350273-A2 COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER The Board of Regents of The University of Texas System (US) 2011-08-03 EP disclosed
WO-2011008495-A2 ARGINASE FORMULATIONS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-01-20 WO disclosed
WO-2010124547-A1 SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-VIRAL AGENTS THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2010-11-04 WO disclosed
US-20100247508-A1 SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-VIRAL AGENTS THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2010-09-30 US disclosed
WO-2010051533-A2 COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-05-06 WO disclosed
US-20100111925-A1 Compositions of Engineered Human Arginases and Methods for Treating Cancer THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-05-06 US disclosed